Oculis (NASDAQ:OCS) Stock Gets Price Target Trim from Guggenheim

Oculis (NASDAQ:OCS) had its target price reduced by Guggenheim to $40.00 in a report published on Wednesday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock.

Several other equities analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Thursday, October 15th. JPMorgan Chase & Co. reduced their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Finally, HC Wainwright restated a “buy” rating and issued a $39.00 price objective on shares of Oculis in a report on Wednesday, October 21st. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Oculis presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.89.

Oculis Trading Up 9.7%

Shares of NASDAQ:OCS traded up $0.66 during midday trading on Wednesday, hitting $7.49. 404,086 shares of the stock were exchanged, compared to its average volume of 307,204. The business’s 50-day moving average price is $9.20 and its 200 day moving average price is $18.35. Oculis has a 12 month low of $6.78 and a 12 month high of $34.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.35 and a current ratio of 8.35. The stock has a market capitalization of $434.27 million, a price-to-earnings ratio of -4.38 and a beta of 0.67.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.10. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.26 million. Analysts predict that Oculis will post -1.83 earnings per share for the current year.

Institutional Trading of Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in Oculis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock worth $1,855,000 after purchasing an additional 5,813 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Oculis in the 3rd quarter valued at $74,000. Koshinski Asset Management Inc. acquired a new stake in shares of Oculis during the first quarter worth $238,000. Himension Capital Singapore PTE. LTD. acquired a new stake in shares of Oculis during the first quarter worth $503,000. Finally, Alps Advisors Inc. increased its position in shares of Oculis by 40.7% during the third quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock worth $762,000 after buying an additional 23,600 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis News Roundup

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: A Zacks analysis says OCS is technically oversold after falling 21.1% over four weeks, which could mean selling pressure is easing. It also cites broader analyst earnings-estimate revisions as a possible catalyst for a trend reversal. Zacks analysis
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $39 price target. The firm raised its FY2026 loss-per-share estimate to $1.63 from $1.72 and slightly improved its Q4 2026 estimate, although Oculis is still expected to report losses. MarketBeat analyst estimate report
• Negative Sentiment: HC Wainwright cut its loss-per-share estimates for Q1–Q3 2027 and lowered its FY2027 estimate to a loss of $1.93 per share from $1.90. These revisions temper the rebound case and point to continued expected losses. MarketBeat analyst estimate report

About Oculis

Oculis is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company’s research is centered on therapies that can be administered directly to the eye, including topical ophthalmic formulations and other approaches designed to improve drug delivery, efficacy, and patient convenience.

Oculis has developed a pipeline addressing ophthalmic conditions such as retinal diseases, diabetic macular edema, dry eye disease, and other disorders that can impair vision.